Abstract
Background: Opicapone (OPC), a once-daily catechol-O-methyltransferase inhibitor, was shown to be effective for end-of-dose motor-fluctuations in Parkinson's disease (PD) patients. We evaluated the efficacy of OPC in patients who switched from placebo (PLC) or entacapone (ENT) to OPC in the 1-year open-label extension (OLE) study of BIPARK-I and ended it on OPC 50-mg.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
